Management of superficial bladder cancer: What is new?

Current Opinion in Urology

Volumn 10, Issue 5, 2000, Pages 447-451

  Malmstrom, P U ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BIOCHEMICAL MARKER; BROPIRIMINE; EPIRUBICIN;

ARTICLE; BLADDER CANCER; CANCER PREVENTION; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG INSTILLATION; FLUID INTAKE; GENE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING CESSATION; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTOSCOPY; FORECASTING; HUMANS; PRACTICE GUIDELINES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 0033822218     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200009000-00014     Document Type: Article

References (28)

1. Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS)
2. Significance of bladder biopsies in Ta, T1 bladder tumors: A report from the EORTC Genito-Urinary Tract Cancer Cooperative Group
3. Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology
4. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal
5. The World Health Organization/International Society of Urological Pathology. Bladder Consensus Conference Committee
6. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications
7. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations
8. Intravesical chemotherapy with epirubicin: A dose response study
9. 5-Year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma
10. BCG immunotherapy of bladder cancer: 20 years on
11. Intravesical therapy for transitional cell carcinoma of the bladder: The community practice
12. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail
13. Sequential bacillus Calmette-Guerin and epirubicin vs. bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study
14. Results of a European comparative randomized study comparing oral bropirimine vs. intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder
15. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder
16. p53 Point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers
17. Fluid intake and the risk of bladder cancer in men
18. Reliability of the routine cytological diagnosis in bladder cancer
19. Utility of the BTA stat test kit for bladder cancer screening
20. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer
21. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat
22. Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract
23. Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas
24. Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: Wide distribution of inhibition rates in bladder cancer and renal cell cancer
25. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer
26. Immunotherapy of bladder cancer targeting p53
27. AD-CD40L transduced tumor cells evoke an effective protection against tumor challenge in a murine urinary bladder cancer model